

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 6-K**

---

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934**

**Date of Report: December 30, 2021**

**Commission File Number: 001-39307**

---

**Legend Biotech Corporation**  
(Exact Name of Registrant as Specified in its Charter)

---

**2101 Cottontail Lane  
Somerset, New Jersey 08873  
(Address of principal executive office)**

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F       Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

## Legend Biotech Announces Appointment of Dr. Ying Huang to the Board of Directors

On December 30, 2021, Legend Biotech Corporation (the “Legend Biotech”) issued a press release announcing that Dr. Ying Huang, Legend Biotech’s Chief Executive Officer and Chief Financial Officer, has been appointed as a director to Legend Biotech’s Board of Directors. Dr. Huang will serve as a Class I director. Dr. Huang will not receive any additional compensation in connection with his service on Legend Biotech’s Board of Directors.

Ying Huang, Ph.D., has served as Legend Biotech’s Chief Executive Officer since September 2020 and as its Chief Financial Officer since July 2019. Prior to joining Legend Biotech, Dr. Huang was a Managing Director and Head of Biotech Equity Research at BofA Securities, Inc. from August 2014 to July 2019, where he led a team of analysts covering more than 30 biotechnology companies including Amgen, Gilead, Celgene, Biogen and others that encompass a wide range of therapeutic areas. Dr. Huang became a biotechnology analyst in 2007 and worked at Wells Fargo (formerly Wachovia), Credit Suisse, Gleacher and Barclays before joining BofA Securities, Inc. Prior to his Wall Street career, Dr. Huang was a Principal Scientist at Schering-Plough (now Merck & Co.) in the Department of Chemical Research focusing on small molecule drug discovery in the therapeutic areas of cardiovascular and central nervous system. He is also the co-author of multiple patents and peer-reviewed publications. Dr. Huang holds a Ph.D. in Bio-organic Chemistry from Columbia University. Dr. Huang also studied at Columbia Business School and in the Special Class for the Gifted Young at the University of Science and Technology of China.

The press release issued by Legend Biotech is attached to this Form as Exhibit 99.1.

This Form 6-K (excluding Exhibit 99.1) is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-257625 and 333-257609) and Form S-8 (File No. 333-239478).

### **EXHIBIT INDEX**

<b>Exhibit</b>	<b>Title</b>
----------------	--------------

<a href="#">99.1</a>	<a href="#">Press Release, dated December 30, 2021.</a>
----------------------	---

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

### LEGEND BIOTECH CORPORATION

(Registrant)

December 30, 2021

By: /s/ Ying Huang

---

Ying Huang, Ph.D.

Chief Executive Officer and Chief Financial Officer

## Legend Biotech Announces Appointment of Dr. Ying Huang to the Board of Directors

SOMERSET, N.J.--(BUSINESS WIRE)--December 30, 2021--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced today that Dr. Ying Huang, Legend Biotech’s Chief Executive Officer and Chief Financial Officer, has been appointed as a director to Legend Biotech’s Board of Directors. Dr. Huang will serve as a Class I director.

“We are delighted to have Dr. Huang join our Board of Directors,” said Sally Wang, Chairwoman of Legend Biotech. “As Legend Biotech’s Chief Executive Officer and Chief Financial Officer, Dr. Huang has been instrumental to Legend Biotech’s progress to date, and his extensive knowledge of Legend Biotech will surely enhance our Board of Directors.”

Ying Huang, Ph.D., has served as Legend Biotech’s Chief Executive Officer since September 2020 and as its Chief Financial Officer since July 2019. Prior to joining Legend Biotech, Dr. Huang was a Managing Director and Head of Biotech Equity Research at BofA Securities, Inc. from August 2014 to July 2019, where he led a team of analysts covering more than 30 biotechnology companies including Amgen, Gilead, Celgene, Biogen and others that encompass a wide range of therapeutic areas. Dr. Huang became a biotechnology analyst in 2007 and worked at Wells Fargo (formerly Wachovia), Credit Suisse, Gleacher and Barclays before joining BofA Securities, Inc. Prior to his Wall Street career, Dr. Huang was a Principal Scientist at Schering-Plough (now Merck & Co.) in the Department of Chemical Research focusing on small molecule drug discovery in the therapeutic areas of cardiovascular and central nervous system. He is also the co-author of multiple patents and peer-reviewed publications. Dr. Huang holds a Ph.D. in Bio-organic Chemistry from Columbia University. Dr. Huang also studied at Columbia Business School and in the Special Class for the Gifted Young at the University of Science and Technology of China.

### About Legend Biotech

Legend Biotech is a global, clinical-stage biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell, T-cell receptor (TCR-T), and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of safe, efficacious and cutting-edge therapeutics for patients worldwide.

We are currently engaged in a strategic collaboration to develop and commercialize our lead product candidate, ciltacabtagene autoleucl (cilta-cel), an investigational BCMA-targeted CAR-T cell therapy for patients living with multiple myeloma. Applications seeking approval of cilta-cel for the treatment of patients with relapsed or refractory multiple myeloma (RRMM) are currently under regulatory review by several health authorities around the world, including the U.S. Food and Drug Administration and the European Medicines Agency.

### Contacts

#### Investor Contacts:

Joanne Choi, Senior Manager of Investor Relations and Corporate Communications, Legend Biotech  
joanne.choi@legendbiotech.com

Crystal Chen, Manager of Investor Relations and Corporate Communications, Legend Biotech  
crystal.chen@legendbiotech.com

#### Press Contact:

Tina Carter, Corporate Communications Lead, Legend Biotech  
tina.carter@legendbiotech.com or media@legendbiotech.com